| Vertex Pharmaceuticals, Inc. - SWOT Analysis | | | | well as a list of products and services and the |
| company profile is the essential source for | | | | latest available statement from Vertex |
| top-level company data and information. Vertex | | | | Pharmaceuticals, Inc. |
| Pharmaceuticals, Inc. - SWOT Analysis examines | | | | Reasons to Purchase |
| the company's key business structure and | | | | - Support sales activities by understanding your |
| operations, history and products, and provides | | | | customers' businesses better |
| summary analysis of its key revenue lines and | | | | - Qualify prospective partners and suppliers |
| strategy. | | | | - Keep fully up to date on your competitors' |
| Vertex Pharmaceuticals (Vertex) is a global | | | | business structure, strategy and prospects |
| biotechnology company engaged in discovering, | | | | - Obtain the most up to date company |
| developing and commercializing small molecule | | | | information available |
| drugs for the treatment of major diseases like | | | | Table of Contents : |
| viral diseases, cystic fibrosis, inflammation, | | | | SWOT COMPANY PROFILE: Vertex |
| autoimmune diseases, cancer, and pain. The | | | | Pharmaceuticals, Inc. |
| company primarily operates in the US. It is | | | | Key Facts: Vertex Pharmaceuticals, Inc. |
| headquartered in Cambridge, Massachusetts and | | | | Company Overview: Vertex Pharmaceuticals, Inc. |
| employed 1,432 people as of December 31, 2009. | | | | Business Description: Vertex Pharmaceuticals, Inc. |
| The company recorded revenues of $101.9 million | | | | Company History: Vertex Pharmaceuticals, Inc. |
| during the financial year (FY) ended December | | | | Key Employees: Vertex Pharmaceuticals, Inc. |
| 2009, a decrease of 41.9% over FY2008. The | | | | Key Employee Biographies: Vertex |
| operating loss of the company was $614 million | | | | Pharmaceuticals, Inc. |
| during FY2009, as compared to an operating loss | | | | Products & Services Listing: Vertex |
| of $462.7 million in FY2008. The net loss was | | | | Pharmaceuticals, Inc. |
| $642.2 million in FY2009, as compared to a net | | | | Products & Services Analysis: Vertex |
| loss of $460 million in FY2008. | | | | Pharmaceuticals, Inc. |
| Scope of the Report | | | | SWOT analysis: Vertex Pharmaceuticals, Inc. |
| - Provides all the crucial information on Vertex | | | | *Strengths: Vertex Pharmaceuticals, Inc. |
| Pharmaceuticals, Inc. required for business and | | | | *Weaknesses: Vertex Pharmaceuticals, Inc. |
| competitor intelligence needs | | | | *Opportunities: Vertex Pharmaceuticals, Inc. |
| - Contains a study of the major internal and | | | | *Threats: Vertex Pharmaceuticals, Inc. |
| external factors affecting Vertex Pharmaceuticals, | | | | Company View: Vertex Pharmaceuticals, Inc. |
| Inc. in the form of a SWOT analysis as well as a | | | | Top Competitors: Vertex Pharmaceuticals, Inc. |
| breakdown and examination of leading product | | | | Location and Subsidiary: Vertex Pharmaceuticals, |
| revenue streams of Vertex Pharmaceuticals, Inc. | | | | Inc. |
| -Data is supplemented with details on Vertex | | | | *Head Office: Vertex Pharmaceuticals, Inc. |
| Pharmaceuticals, Inc. history, key executives, | | | | *Other Locations and Subsidiaries: Vertex |
| business description, locations and subsidiaries as | | | | Pharmaceuticals, Inc. |